Charles River Laboratories Sees 7.39 Billion Turnover Surge to 156th Ranking Despite 28.13% Stock Drop

On April 10, 2025, Charles River Laboratories (CRL) experienced a significant trading day with a turnover of 7.39 billion, marking an 182.9% increase from the previous day. This surge placed CRL at the 156th position in the day's stock market rankings. However, the stock price of Charles River Laboratories (CRL) fell by 28.13%.

The U.S. Food and Drug Administration (FDA) has announced a significant shift in its drug development protocols, moving away from traditional animal testing. This change is expected to impact the creation of monoclonal antibody therapies and various other pharmaceuticals. The FDA plans to adopt methods more closely aligned with human biology, which are anticipated to enhance the safety of new drugs and streamline the drug approval process. This shift is likely to reduce the necessity for animal testing, thereby lowering research costs and eventually the cost of drugs for consumers. The FDA believes that these "human-relevant" methods will expedite evaluations and improve overall drug safety.

In response to this development, investors are closely monitoring the stock performance of Charles River Laboratories. As a company that supplies nonhuman primates for testing, Charles River may experience significant market reactions due to these regulatory changes. The shift in FDA policy emphasizes a growing trend towards more ethical and efficient drug development practices.

Charles River Laboratories has also enacted a series of staffing cuts in recent months. In February, a company spokesperson confirmed that it would be reducing its workforce, which could further impact its stock performance and market position.